TruthArchive.ai - Related Video Feed

RNA vaccines are short-lived copies of chromosomal recipes that produce selected antigens. Billions of copies are injected into the body, made possible by using plasmids derived from bacteria. These plasmids contain the DNA recipes and can be manipulated to include genes for viral proteins. After bacterial decay, the plasmids are harvested and used as templates to produce RNA copies. The RNA molecules are then packaged into lipid nanoparticles to protect them in the bloodstream. These nanoparticles act as trojan horses, entering cells and releasing their cargo to produce the desired gene product. However, if the recipe comes from an alien book, our immune system will attack the cell.

In Chicago, Medicago uses plants as bioreactors to grow vaccines. They insert virus gene sequences into Agrobacterium tumphatians bacteria, which is then absorbed by the plants. After a few days in a greenhouse, the plants start producing virus-like particles, the key component of the vaccines.

In Medellin, Colombia, the world's largest mosquito factory is producing 30 million mosquitoes per week for the World Mosquito Program. By introducing Wolbachia bacteria into the mosquitoes, their ability to transmit diseases like dengue is stopped. The process involves releasing Wolbachia-infected mosquitoes into the wild population through mating. The factory houses mosquito eggs, larvae, and pupae, which are sorted by sex to manipulate the sex ratio. The mosquitoes are fed blood and then either packaged as eggs or released as adults into the field. With over half the world's population at risk of these diseases, the goal is to scale and deliver this solution to communities in need.

The symposium covers the potential safety and threat of “replicating” vaccines, especially LepriCon (leprecon) vaccines, in the context of Covid-19 vaccines and genome‑editing concepts. The speakers present a chain of claims and concerns, some drawing on reports and others presenting theories about how these next‑generation vaccines could behave in humans and populations. Key points and claims presented - Emerging mechanisms and risks: The panel notes that blood vessel inflammation and thrombosis mechanisms are increasingly observed, including in vaccine contexts, with examples from individuals who needed limb amputation and others who developed severe vascular events after vaccination. One case involved a 70‑year‑old man who, after a third dose, developed embolic events necessitating shoulder joint surgery, and another where a 60‑year‑old man developed acute limb ischemia and died; both are presented as suggesting a serious vascular mechanism linked to vaccination, though causal connections are not established. - Replicating/vector vaccines and their concerns:荒川博士 and others discuss LepiCon vaccines as vaccines that replicate inside the body. The concept involves “replicating viral vectors” where the genome can mutate and evolve during replication. The green‑highlighted segment in a slide (the antigen gene) plus a blue/orange segment (replicating gene cassette) is used to describe how LepriCon vaccines are designed to carry viral genes and replicate, with the assertion that replication, mutation, and recombination can occur, potentially generating new variants inside the host. - Differences from conventional vaccines: The discussion contrasts LepriCon vaccines with standard mRNA vaccines. In conventional mRNA vaccines, messenger RNA is delivered and translated into antigen proteins, then degraded; in LepriCon vaccines, replicating RNA/DNA can persist and continue producing antigen, with mutation and recombination possible. The panel emphasizes that LepriCon vaccines use replicating/copying mechanisms and that the genetic material can be copied in ways that differ from natural human biology, potentially creating unpredictable variants. - Central dogma and exceptions: The speakers reference the central dogma (DNA → RNA → protein) but note exceptions in viruses, including RNA viruses that can reverse‑transcribe to DNA (retroviruses) and RNA viruses that replicate RNA directly. They discuss how LepriCon vaccines would rely on replicative processes that do not follow the usual linear flow and why this could complicate predictions about safety and behavior in humans. - Potential for unintended spread and environmental impact: A major concern raised is that self‑replicating vectors could spread beyond the vaccinated individual, via exosomes or other intercellular transport, creating secondary infections or non‑target spread. Exosomes could ferry replicating genetic material, raising fears of new infection chains or “outbreaks” stemming from the vaccine itself, and even suggesting the possibility of vaccination‑induced spread akin to an attenuated or modified pathogen. - Safety signals and immunology concerns: The discussion touches on immune system risks, including immune dysregulation, autoimmune phenomena, and unexpected inflammatory responses. IGG4‑related disease is highlighted as a potential adverse outcome post‑vaccination, with descriptions of glandular and systemic involvement and the idea that high IGG4 levels could have immunosuppressive effects that alter responses to infection or vaccination. The panel notes observed increases in certain immunoglobulin subclasses after multiple LepriCon doses and discusses the possibility of immune tolerance or enhanced immune responses that could be harmful. - Historical and theoretical context: References are made to past epidemics and speculative pandemics caused by misused or dangerous vaccine platforms, drawing on central molecular biology concepts and historical anecdotes about how vaccines can be designed and misused. The discussion frames LepriCon vaccines as a high‑risk platform that could, in theory, generate recombinants, escape mutations, or cause unintended immune and inflammatory consequences. - Clinical and regulatory implications: The speakers call for caution, arguing that more evidence is needed before approving or widespread use of LepriCon vaccines. They emphasize the need for long‑term observation and transparent communication about risks, and criticize the potential for insufficient understanding among healthcare workers and the public. They also urge that any future vaccine development should consider the possibility of genome editing, recombination, and exosome‑mediated spread, and stress the importance of not underestimating possible adverse effects. - Real‑world observations and skepticism about hype: Several speakers underscore that the danger is not merely hypothetical; there are reports of adverse events, including stroke‑like conditions, inflammatory diseases, and immune dysregulation in vaccinated individuals. They stress that the evolution and mutation of replicating vaccines could outpace current surveillance methods, and that “information manipulation” or lack of transparent reporting could mislead the public about risks. - Final reflections and call to action: The concluding messages advocate recognizing the potential failures of messenger RNA vaccines and acknowledging that both conventional and replicating platforms may carry risks. The speakers urge ongoing critical analysis, cautious progression, and robust verification of claims through transparent, independent investigation. They close with thanks to the organizers and a hope that the discussion may contribute to broader public awareness and informed decision‑making. Notable emphasis and unique considerations - The core concern centers on LepriCon vaccines’ replication, mutation, and potential to spread beyond the vaccinated person; exosome transport and genomic/cellular integration are highlighted as mechanisms that could generate new risks not present with non‑replicating vaccines. - The discussion stresses that IGG4 responses could become alarmingly high after certain doses, potentially leading to immunosuppressive effects or autoimmune phenomena, and presents IGG4‑related disease as a potential complication to monitor. - The speakers insist that safety and transparency are paramount, and that misinformation or optimistic narratives about rapid vaccine development could lead to harm if new platforms are adopted without comprehensive evaluation. Overall, the symposium foregrounds cautious scrutiny of replicating vaccine platforms, frames potential biological and regulatory risks, and calls for careful, evidence‑based assessment before broader deployment.

Chicago's manufacturing facility is using a unique technology called virus like particles to grow vaccines. Medicago, the company behind this process, uses plants as mini bioreactors. They start by synthesizing the virus code into a biological product using the gene sequence. The code is inserted into bacteria called Agrobacterium tungfaciens, which is then submerged with the plants in a bacterial bath. The plants absorb the information and continue growing in a controlled greenhouse for at least 4 days. During this time, they start producing virus like particles, which are the crucial ingredient for the vaccines.

The speakers discuss the need for a new and improved method of vaccine production. They acknowledge the challenges of transitioning from the current egg-growing process to a more efficient method. The process of proving the effectiveness of a new vaccine and going through clinical trials can take up to a decade. They suggest the need for a disruptive entity that is not bound by bureaucratic processes to address the problem of influenza. They also mention the possibility of using RNA sequences from novel avian viruses in China to create vaccines that can be self-administered through patches.

UC Riverside and UC Berkeley have developed vaccines in lettuce and tomatoes, while tobacco companies have done so in tobacco products. The concern is about proper dosing and labeling of these products to ensure consumer safety. The bill aims for transparency in grocery stores selling vaccine-containing produce. The technology is still in development, but the goal is to prevent issues like improper dosing seen in the cattle industry. The discussion highlights the need for consumer awareness and regulation in this emerging field.

In Medellin, Colombia, the world's largest mosquito factory is producing 30 million mosquitoes per week for the World Mosquito Program. They are using Wolbachia bacteria to stop the transmission of diseases like dengue, Zika, and chikungunya. The factory starts with mosquito eggs, which hatch into larvae and then pupae. The males and females are sorted, with more females being desired. The adult mosquitoes are either packaged as eggs in gelatin capsules or released directly into the field. The goal is to scale this solution and deliver it to communities worldwide that are affected by these diseases.

The NIH is developing a universal vaccine that addresses the entire phylum of viruses. This vaccine mimics natural immunity and is effective against any kind of mutation. It doesn't drive the virus to mutate. The researchers believe it could be effective not only against coronaviruses but also against influenza. The vaccine is described as much safer and much more effective. The exchange then notes that Mark, did you take your question again? and Mark is prompted to ask his question.

Chicago's manufacturing facility is using a unique method called virus like particle technology to grow vaccines. Medicago, the company behind this process, starts by synthesizing the gene sequence of a virus into a biological product. They insert this code into bacteria, which then carries it into plant cells. The plants absorb the code and begin producing virus like particles, the key ingredient of the vaccines. After a four-day growth period in a controlled greenhouse, the plants are ready for vaccine production.

In Medellin, Colombia, the world's largest mosquito factory is producing 30 million mosquitoes per week for the World Mosquito Program. They are using Wolbachia bacteria to prevent the transmission of diseases like dengue, Zika, and chikungunya. The process involves introducing Wolbachia into the mosquitoes, which then pass it on to the wild mosquito population through mating. The factory houses mosquito eggs, larvae, and pupae, which are sorted by sex to manipulate the sex ratio in the cages. The mosquitoes are fed blood and can be released into the field either as eggs or as adults. The program aims to scale and deliver this solution to communities worldwide.

We are in Medellin, Colombia at the world's largest mosquito factory for the World Mosquito Program. We produce 30 million mosquitoes a week to combat diseases like dengue and Zika by introducing Wolbachia bacteria into the mosquito population. The process starts with eggs, then larvae, pupae, and finally adult mosquitoes. We sort males from females to control the sex ratio. The mosquitoes are fed blood and then released into the field to mate and spread Wolbachia.

A bill in Tennessee proposes labeling food with vaccines, while Idaho has a similar bill. Edible vaccines are being studied at UC Riverside, where scientists are exploring the use of plants like lettuce to produce mRNA vaccines. Traditionally, vaccines are grown in eggs or animal cells, but plant-based vaccines are being developed. Genetic editing is being used to create edible vaccines in plants like bananas, potatoes, tomatoes, lettuce, rice, wheat, soybeans, and corn. Medicago is using gene editing to turn plants into mini bioreactors for vaccine production. There are concerns about mRNA vaccines being used on livestock, with the potential for transference to humans through meat consumption. Transparency laws are being debated to inform consumers about genetically modified products in livestock.

FluBlock utilizes insect cells for rapid manufacturing, representing innovative biotechnology. Traditional flu vaccines require adapting influenza strains to cell or egg cultures, potentially resulting in a vaccine antigen that differs from the circulating antigen. FluBlock, using baculovirus technology, can proceed directly from sequence to manufactured protein faster, eliminating the need for adaptation. This is a key advantage.

Chicago's manufacturing facility is using a technology called virus like particles to grow a new type of vaccine. Medicago, the company behind this process, uses plants as mini bioreactors. They start by obtaining the gene sequence of a virus and insert it into bacteria called Egerobacterium tumfaciens. The plants are then submerged in a bath with the bacteria, allowing the genetic information to be absorbed by the plant cells. The air between the plant cells is replaced with liquid using a vacuum. After the plants' bacterial bath, they are returned to a controlled greenhouse.

The most urgent invention is a COVID-19 vaccine, which teaches the immune system about the pathogen, specifically the coronavirus and its spike protein. The spike protein grabs cells and causes them to make billions of copies of the virus. Vaccines expose the body to something that looks like the virus, prompting the body to create antibodies to kill it. Vaccine creation usually involves injecting part of the virus's shape. This can be the whole virus, attenuated, or killed. Often, just a piece of the virus or the spike is used, eliminating the risk of causing disease. A promising new method is the RNA vaccine, which uses instructions to make the spike's shape. The Gates Foundation and partners are exploring these efforts. Creating a new vaccine typically takes at least 5 years, but there is optimism that a vaccine will be available in the next 18 months, produced in volume, and accessible worldwide, which will end the pandemic.

In Medellin, Colombia, the world's largest mosquito factory is producing 30 million mosquitoes per week for the World Mosquito Program. The goal is to combat diseases like dengue, Zika, and chikungunya by introducing a bacteria called Wolbachia into the mosquitoes, which stops their ability to transmit dengue. The factory houses millions of mosquito eggs, which hatch into larvae and eventually become adult mosquitoes. The males and females are sorted to manipulate the sex ratio in the cages. The mosquitoes are fed blood and then released into the field once they are fully grown.

The video discusses the concept of edible vaccine therapy for combating human diseases, particularly COVID-19. It explains that this technology has been available for decades and differs from traditional vaccines. Instead of introducing a pathogen to stimulate the body's immune response, edible vaccines program the body to produce specific substances. These vaccines can be created by injecting fruits, vegetables, or farm animals with the desired pathogen, which is then packaged as a vaccine. The speaker also mentions the potential benefits and challenges of this approach. Additionally, they briefly mention the idea of COVID mRNA making humans superhuman.

The most urgent invention is a COVID-19 vaccine, which teaches the immune system about the pathogen, specifically the coronavirus and its spike protein. The spike protein grabs cells and causes them to make billions of copies of the virus. Vaccines expose the body to something that looks like the virus, prompting the body to create antibodies to kill it. Vaccine creation usually involves injecting part of the virus's shape. This can be the whole virus, attenuated, or killed, or just a piece of the virus or the spike. A promising new method is the RNA vaccine, which uses RNA and DNA to provide instructions to make the spike shape. The Gates Foundation and partners are exploring these efforts. Creating a new vaccine typically takes at least 5 years, but there is optimism that a vaccine will be available in the next 18 months, produced in volume, and accessible to everyone, which is how the pandemic will end.

I've been involved in over 50 vaccines, including mRNA vaccines. mRNA is like DNA, giving cells instructions to make proteins. This technology was originally for gene therapy, now used for vaccines. It's a new, experimental technology never used in humans before COVID. Animal studies were skipped for COVID vaccines, a novel approach.

We are in a digital and scientific revolution, hacking the software of life with mRNA. Our body is made of organs, organs of cells, and in each cell is messenger RNA transmitting DNA information to proteins. This "operating system" can be altered to impact diseases like the flu and cancer. For instance, instead of injecting virus proteins for a flu vaccine, mRNA instructions can teach the body to make its own protection. This mRNA technology has vast potential for disease prevention and treatment.

The company Biontech in Mainz is working on a new method for producing vaccines. They use mRNA, a natural molecule found in every cell, to stimulate the body to produce the antidote itself. This personalized approach allows them to create a vaccine in just two to four weeks, making it possible to respond quickly to pandemics. The new vaccine is currently undergoing clinical trials, and if successful, it could be approved within five to six years. This breakthrough method could revolutionize the fight against time. However, it remains to be seen which of these new developments will come out on top once all the studies are completed.

The most urgent invention is a COVID-19 vaccine, which teaches the immune system about the pathogen, specifically the coronavirus and its spike protein. The spike protein grabs cells and causes them to make billions of copies of the virus. Vaccines expose the body to something that looks like the virus, prompting the body to create antibodies to kill it. Vaccine creation usually involves injecting part of the virus's shape. This can be the whole virus (attenuated), a killed virus, or just a piece of the virus, like the spike. A promising new method is the RNA vaccine, which uses instructions to make the spike's shape. The Gates Foundation and partners are exploring these efforts. Creating a new vaccine typically takes at least 5 years, but there is optimism that a vaccine will be available in the next 18 months, produced in volume, and accessible worldwide, which is how the pandemic will end.

Moderna and BioNTech used the first sequence of the SARS CoV-2 genome, published on January 10th, to develop their vaccines. Moderna relied solely on the published data and never had the live virus on their site. This highlights the significance of digitizing biology, as Moderna, a leading company in biology, faced a software problem rather than a biological one.

We are discussing vaccine development in response to new variants and subvariants. Currently, we have the advantage of increased manufacturing capacity compared to 2020. Back then, we only produced 100,000 doses in a year, but now we are capable of producing much more to address the ongoing challenges posed by different strains of the virus.